Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #80820 on Biotech Values
DewDiligence
07/15/09 7:14 PM
#80901 RE: genisi #80820
Acquired Premium Deal iHub Company Buyer to Market Value Date Reference GNLB GSK 465% $57M 10/08 #msg-33209281 MEMY Roche 319% $50M 11/08 #msg-33787598 KOSN BMY 233% $190M 5/08 #msg-29647147 MGRM LH 171% $155M 6/09 #msg-38960958 COLY PFE 167% $165M 11/07 #msg-24600805 NTMD Deerfield 158%‡‡‡ $36M 1/09 #msg-35132470 EYE ABT 149% **$2.8B 1/09 #msg-34762429 IOMI Intercell 147% $190M 5/08 #msg-29232165 BTRX Stiefel 136% $150M 6/08 #msg-30201906 Tepnel GPRO 126% $132M 1/09 #msg-35221710 SGXP LLY 119% $64M 7/08 #msg-30547648 ENCY PFE 118% $350M 2/08 #msg-26978155 TRCA Ipsen 104% $660M 6/08 #msg-29795183 CRY.to MDT 97% $380M 9/08 #msg-32421462 Speedel NVS 94% $880M 7/08 #msg-30588524 MNT JNJ 92% $1.1B 11/08 #msg-33879830 SIRT GSK 85% $620M 4/08 #msg-28705020 CVTX GILD *‡76% $1.4B 3/09 #msg-36225695 IDEV ENDP *†74% *†$370M 1/09 #msg-34592416 LEVP VPHM ††73% ††$510M 7/08 #msg-30704409 TARG MDCO ***72% $42M 1/09 #msg-34774402 Ventana Roche 72% $3.4B 1/08 #msg-30912677 Jerini Shire *71% $520M 7/08 #msg-30452872 AAH.AX CEPH 69% $207M 2/09 #msg-35956544 Acambis SNY 64% $550M 7/08 #msg-30990498 SCRX Shionogi 61% $1.4B 9/08 #msg-31859174 IDMI Takeda 55% $75M 5/09 #msg-37898204 ALO KG ‡†54% $1.6B 11/08 #msg-33763449 MEDI AZN ‡‡53% $15.2B 4/07 #msg-19020387 MLNM Takeda 53% $8.8B 4/08 #msg-28365383 PCOP LGND ***52% $75M 9/08 #msg-32404474 OMRI JNJ ‡*51% $465M 11/08 #msg-33762745 IMCL LLY †††51% $6.5B 10/08 #msg-32662830 CRGN CLDX 50% $40M 5/09 #msg-38262967 PHRM CELG 46% $2.9B 11/07 #msg-24645394 BRL TEVA 42% **$9.0B 7/08 #msg-30792830 MOGN Eisai 39% $3.9B 12/07 #msg-25163775 SGP MRK 34% $41B 3/09 #msg-36140327 CGPI Galderma 30% $420M 2/08 #msg-28286522 WYE PFE 29% $68B 1/09 #msg-35077617 APPX Fresenius †29% $940M 7/08 #msg-30498388 Zentiva SNY ‡‡26% $2.6B 9/08 #msg-32327005 NOVN Hisamitsu 22% $428M 7/09 #msg-39515681 CGRB JNJ 16% $970M 5/09 #msg-38039851 DNA Roche 16% †*$46.8B 3/09 #msg-36224175 ARI.to Roche ‡15% $190M 7/08 #msg-30904056 CEGE BPAX 6% $38M 6/09 #msg-39163410 PGLA Avexa ® ® 12/08 #msg-34341452 NUVO ARCA ® ® 9/08 #msg-32420015 NOVC Transcept ® ® 9/08 #msg-31869987 ®Reverse merger with private or non-US company. ‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor. ‡‡Premium relative to commencement of bidding. ‡‡‡To be liquidated by Deerfield following failed merger with Archemix; premium relative to 11/18/08 date of Archemix deal. ‡†Based on closing price 8/21/08, the day before KG announced initial buyout offer. ‡*Based on 11/20/08 close. †Premium reaches 63% if earn-out met. ††Premium and deal value based on 0.45/sh of contingent payments. †††Premium relative to 7/30/08 close, the day before BMY announced first buyout offer. †*Price for 44% of DNA not already owned. *199% premium to volume-weighted price during preceding 3 months. **Deal value includes assumption of debt. ***Premium and deal value exclude contingent payouts. *‡Premium relative to 1/26/09, the day before Astellas announced $16/sh offer. *†Premium includes estimated value of contingent payouts, but listed deal value excludes them.